drugset / Trial / NCT07335913

Phase 1 Study of SBS-147 in Healthy Adults

NCT07335913 ↗

RandomizedSequentialQuadruple-blindTreatment

Summary

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Timeline

Start
2026-01-08
Primary completion
2027-01-31
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject SBS-147 Unknown — Oral

Indications

No indication recorded.